Icm Co. Ltd.

This early-phase study tests a single injection of ICM-203, a gene therapy that delivers a gene to promote cartilage growth and reduce inflammation in the knee. About 18 adults with mild to moderate knee osteoarthritis will receive escalating doses to check safety and whether it …

This study follows 16 people who previously received ICM-203 (a gene therapy) or a placebo for knee osteoarthritis. Researchers will track delayed side effects and measure changes in knee pain and function over time. The goal is to understand the long-term safety and effectivenes…